Share on StockTwits

Antares Pharma (NASDAQ:ATRS) Director Robert P. Roche, Jr. purchased 5,000 shares of Antares Pharma stock on the open market in a transaction dated Wednesday, August 13th. The stock was purchased at an average cost of $1.96 per share, for a total transaction of $9,800.00. Following the purchase, the director now directly owns 28,172 shares in the company, valued at approximately $55,217. The purchase was disclosed in a filing with the SEC, which is available at this link.

Antares Pharma (NASDAQ:ATRS) traded down 1.84% on Friday, hitting $2.13. 543,142 shares of the company’s stock traded hands. Antares Pharma has a 1-year low of $1.87 and a 1-year high of $5.15. The stock has a 50-day moving average of $2.29 and a 200-day moving average of $3.25. The company’s market cap is $277.9 million.

Antares Pharma (NASDAQ:ATRS) last posted its quarterly earnings results on Thursday, August 7th. The company reported ($0.07) earnings per share for the quarter, meeting the analysts’ consensus estimate of ($0.07). The company had revenue of $6.30 million for the quarter, compared to the consensus estimate of $6.43 million. On average, analysts predict that Antares Pharma will post $-0.24 earnings per share for the current fiscal year.

Antares Pharma, Inc (NASDAQ:ATRS) is a pharma company that focuses on self-injection pharmaceutical products and technologies and topical gel-based products.

Receive News & Ratings for Antares Pharma Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.